Global Carbetocin (Duratocin) Market Size By Type (Tablets, Injection), By Application (Oxytocic, Antihemorrhagic), By Region, And Segment Forecasts, 2023 to 2032

The Global Carbetocin (Duratocin) Market was valued at USD 119.4 million in 2023 and is projected to reach USD 208.7 million by 2031, growing at a CAGR of 7.2% during the forecast period (2023–2031). Carbetocin, a long-acting synthetic oxytocin analogue, is primarily used to prevent uterine atony and postpartum hemorrhage (PPH) following caesarean sections or vaginal delivery. Its increasing global demand is driven by rising awareness around maternal health, growing caesarean delivery rates, and ongoing efforts by health organizations to reduce maternal mortality, especially in low-income countries.

Drivers:

1. Rising Prevalence of Postpartum Hemorrhage (PPH):

PPH is a leading cause of maternal mortality globally. Carbetocin has shown greater efficacy and longer duration of action than traditional oxytocin, making it increasingly preferred in clinical settings.

2. Increased Global Caesarean Section Rates:

With the global caesarean delivery rate steadily rising—especially in developing countries—the use of uterotonic drugs like carbetocin is also surging to reduce complications.

3. WHO Recommendation for Heat-Stable Carbetocin:

The World Health Organization’s endorsement of heat-stable carbetocin for PPH prevention in low-resource settings is fostering widespread adoption, particularly where cold-chain storage of oxytocin is impractical.

Restraints:

1. High Cost Compared to Oxytocin:

Carbetocin remains significantly more expensive than oxytocin, making it less accessible for budget-constrained healthcare systems, especially in underdeveloped regions.

2. Limited Accessibility in Emerging Markets:

Despite its clinical advantages, regulatory approvals and availability are still limited in some low- and middle-income countries, impeding overall market expansion.

Opportunity:

1. Market Penetration in Low-Income and Middle-Income Countries:

With increased global attention on reducing maternal mortality, NGOs and health authorities are expected to fund the procurement of carbetocin, especially in Africa and South Asia.

2. Development of Generic and Biosimilar Versions:

The expiration of patents in certain regions will lead to the launch of cost-effective generic versions, expanding access and driving future growth.

Market by System Type Insights:

Based on system type, the Heat-Stable Carbetocin segment accounted for the dominant share in 2023. It eliminates the need for refrigeration and offers enhanced logistical benefits in tropical and low-resource environments. The Conventional Carbetocin segment remains in use in developed markets where cold chain infrastructure is readily available but is expected to grow more slowly.

Market by End-Use Insights:

By end-use, Hospitals emerged as the largest segment in 2023, owing to the high volume of deliveries, especially caesarean sections, that require immediate administration of uterotonics. Maternity Clinics are expected to witness the fastest growth, driven by their increasing number in rural and semi-urban areas in emerging markets.

Market by Regional Insights:

Asia-Pacific led the global carbetocin market in 2023, supported by the high birth rate, increasing institutional deliveries, and progressive maternal health initiatives. Latin America and Africa are projected to witness the fastest growth due to global aid programs and increased public sector adoption of heat-stable carbetocin. North America and Europe maintain steady demand due to advanced healthcare systems and clinical preference for carbetocin during scheduled caesareans.

Competitive Scenario:

Key players in the Global Carbetocin (Duratocin) Market include Ferring Pharmaceuticals, Endo International, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries, Pfizer Inc., and Cipla Ltd. Companies are focusing on expanding regulatory approvals, developing biosimilars, and engaging in partnerships with international health bodies.

In 2023, Ferring Pharmaceuticals expanded its licensing agreement with WHO to facilitate wider distribution of heat-stable carbetocin in low-income countries.

In 2024, Sun Pharma announced its intention to enter the carbetocin market with a heat-stable generic targeting Asian markets.

Teva launched clinical trials for its biosimilar carbetocin variant aimed at capturing the North American hospital segment.

Scope of Work – Global Carbetocin (Duratocin) Market

Key Market Developments:

July 2023: Ferring Pharmaceuticals initiated a global rollout of its WHO-backed heat-stable carbetocin formulation across Sub-Saharan Africa.

February 2024: Pfizer announced a partnership with NGOs to provide subsidized carbetocin in Southeast Asia.

May 2024: Cipla received marketing approval for its generic version of carbetocin in the Indian market.

FAQs:

1. What is the current market size of the Global Carbetocin (Duratocin) Market?

The market was valued at USD 119.4 million in 2023.

2. What is the major growth driver of the Global Carbetocin (Duratocin) Market?

The major driver is the increasing incidence of postpartum hemorrhage and the adoption of carbetocin in caesarean deliveries.

3. Which is the largest region during the forecast period in the Global Carbetocin (Duratocin) Market?

Asia-Pacific is expected to remain the largest and fastest-growing region.

4. Which segment accounted for the largest market share in Global Carbetocin (Duratocin) Market?

The Heat-Stable Carbetocin segment accounted for the largest share in 2023.

5. Who are the key market players in the Global Carbetocin (Duratocin) Market?

Ferring Pharmaceuticals, Endo International, Pfizer Inc., Sun Pharmaceutical Industries, Teva Pharmaceuticals, and Cipla Ltd. are the key players.